Wegovy: A Promising Weight Loss Drug for Heart Failure Patients
A clinical trial funded by Novo Nordisk has found that the weight loss drug semaglutide, sold as Wegovy, significantly reduced symptoms of heart failure with preserved ejection fraction (HFpEF) and led to greater weight loss among people with obesity. Patients who received a weekly dose of semaglutide showed improvements in symptoms such as fatigue, shortness of breath, and swelling, as well as improved exercise function. They also lost an average of 13% of their body fat. The results suggest a potential paradigm shift in the clinical management of HFpEF in people with obesity. Novo Nordisk plans to file for approval of Wegovy's label update in the US and EU in 2024.
- Weight loss drug Wegovy helps people with common type of heart failure, trial finds The Hill
- Weight-loss drug Wegovy produces ‘largest benefit ever seen’ for patients with most common form of heart failure, trial finds CNN
- Wegovy, Ozempic can help with heart failure symptoms, study finds New York Post
- Weight-loss drug can reverse heart failure symptoms, study finds The Guardian
- Wegovy Scores HFpEF Benefits in People With Obesity Medscape
Reading Insights
0
10
2 min
vs 3 min read
78%
506 → 111 words
Want the full story? Read the original article
Read on The Hill